ストックスクリーナーアプリを入手
15.03
4.09%
0.59
前日終値:
$14.44
開ける：
$14.8
24時間の取引高:
3.11M
Relative Volume:
3.08
時価総額：
$923.71M
収益：
-
当期純損益:
$-221.04M
株価収益率:
-4.0465
EPS:
-3.7143
ネットキャッシュフロー:
$-178.65M
1週間 パフォーマンス:
+15.79%
1か月 パフォーマンス:
+1.08%
6か月 パフォーマンス:
+50.60%
1年 パフォーマンス:
+84.19%
1日の値動き範囲:
$14.34
$15.56
1週間の範囲:
$12.79
$15.56
52週間の値動き範囲:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Compare CGEM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
15.03 | 923.71M | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-17 | 開始されました | Citigroup | Buy |
| 2026-02-02 | 開始されました | Guggenheim | Buy |
| 2025-08-21 | 再開されました | H.C. Wainwright | Buy |
| 2025-06-11 | 再開されました | Stifel | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-05-01 | 開始されました | Stifel | Buy |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-06-15 | 開始されました | TD Cowen | Outperform |
| 2022-11-21 | 開始されました | BTIG Research | Buy |
| 2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 開始されました | Evercore ISI | Outperform |
| 2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 開始されました | SVB Leerink | Outperform |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan
Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares - Stock Titan
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options - Stock Titan
Cullinan Therapeutics Inc (CGEM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cullinan Therapeutics Inc (CGEM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cullinan Therapeutics Inc (CGEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com India
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
CGEM Stock Price, Quote & Chart - ChartMill
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $33 to $46 - Moomoo
Cullinan Therapeutics reports remissions in SLE, RA with CLN-978 - scanx.trade
William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
William Blair reiterates Cullinan Oncology stock rating on trial data - Investing.com
CGEM: CLN-978 and velinotamig show breakthrough efficacy and safety in refractory autoimmune diseases - TradingView
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune DiseasesSlideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha
Cullinan Therapeutics (CGEM) Reports Positive Clinical Developme - GuruFocus
CGEM: T cell engagers show robust efficacy in RA and SLE, with expanded trials planned for 2027 - TradingView
Cullinan reports clinical data for autoimmune drug candidates - Investing.com UK
CGEM: CLN-978 and velinotamig advance toward Phase 2 after strong efficacy and safety in SLE and RA - TradingView
Cullinan reports clinical data for autoimmune drug candidates By Investing.com - Investing.com South Africa
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data - TipRanks
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps - Moomoo
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - The Manila Times
Cullinan Therapeutics Shares New Clinical Data Across Its - GlobeNewswire
Cullinan Therapeutics shares positive Phase 1 data for CLN-978 and velinotamig, outlines next‑stage plans - TradingView
Cullinan Therapeutics (NASDAQ: CGEM) shares new autoimmune trial results - Stock Titan
Cullinan Aims for Autoimmune 'Reset' with T Cell Engager Data - BriefGlance
Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research - Traders Union
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Cullinan TherapeuticsExpanding The Reach Of T Cell Engagers Beyond Cancer - RTTNews
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-978 CD19xCD3 T Cell Engager in SLE and RA at EULAR 2026 Congress - Minichart
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data - TipRanks
Cullinan Therapeutics shares Phase 1 CLN-978 data showing deep B-cell depletion and clinical responses - TradingView
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data - Stock Titan
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at E - GuruFocus
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at EULAR Congress - GuruFocus
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):